by Fred Dumais | Jun 22, 2023 | News Release
MONTREAL, QUEBEC, June 22, 2023 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that Ms. Tamara Close and Mr. Didier Leconte have joined its Board of Directors. Following the...
by Fred Dumais | Jun 13, 2023 | Communiqué de presse
Sixième trimestre consécutif de croissance des revenus à 13,6 millions $ au T2-2023, en hausse de 184% par rapport au T2-2022 Sixième trimestre consécutif de réduction de la perte du BAIIA ajusté à 1,7 million $, soit une amélioration de 53 % par rapport au T2-2022,...
by Fred Dumais | Jun 13, 2023 | News Release
Sixth consecutive quarter of revenue growth at $13.6 million in Q2-23, up 184% over Q2-22. Sixth consecutive quarter of adjusted EBITDA loss reduction at $1.7 million, a 53% improvement over Q2-22, and down 24% compared to Q1-23 Physicians prescribing Enerzair and...
by Fred Dumais | Jun 7, 2023 | Communiqué de presse
MONTRÉAL (QUÉBEC), le 7 juin 2023 – Valeo Pharma inc. (TSX : VPH, OTCQB : VPHIF, FSE : VP2) (la « Société » ou « Valeo Pharma »), une société pharmaceutique canadienne, a annoncé aujourd’hui qu’elle divulguera ses résultats financiers et...
by Fred Dumais | Jun 7, 2023 | News Release
MONTREAL, QUEBEC , June 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the second quarter ended April 30, 2023 on...
